Chronic kidney disease Trials in San Antonio, United States
Conditions / Chronic kidney disease / San Antonio, United States
Chronic kidney disease has been the subject of sustained clinical investigation across multiple research sites.
64 total trials for this combination
Showing top 10 of 64 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06131372 | A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo | COMPLETED | PHASE2 |
| NCT05021835 | ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT05803421 | A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk | COMPLETED | — |
| NCT05803421 | A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk | COMPLETED | — |
| NCT05803421 | A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk | COMPLETED | — |
| NCT05196035 | A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | RECRUITING | — |
| NCT02540993 | Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease | COMPLETED | PHASE3 |
| NCT05457283 | A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria | RECRUITING | — |
| NCT04595370 | Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease | COMPLETED | PHASE2 |
| NCT00503698 | The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis | TERMINATED | PHASE3 |